

**EudraCT number:** 2019-003131-31

**Sponsor Code:** M19-956

**Title:** A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren's Syndrome.

Please note the following: Although a EudraCT number was assigned for this trial, the study was prematurely terminated (not initiated). Therefore, AbbVie will not be submitting study results.